RMAT status awarded to experimental cell therapy KYV-101 for treating MG
An open-label, multicenter Phase 2 clinical trial will test KYV-101 in people with refractory MG and positive for self-reactive antibodies.| Myasthenia Gravis News
An open-label, multicenter Phase 2 clinical trial will test KYV-101 in people with refractory MG and positive for self-reactive antibodies.| Myasthenia Gravis News
